Form 4: Nuvation Bio Inc. Director, Kathryn E. Falberg, Reports Stock Option Grant

Kathryn E. Falberg, a director of Nuvation Bio Inc., reported the acquisition of stock options for 200,801 shares on September 3, 2024.

Summary

• On September 3, 2024, Kathryn E. Falberg, a director of Nuvation Bio Inc. (NUVB), reported a transaction involving derivative securities.
• Falberg acquired stock options for 200,801 shares of Class A Common Stock at an exercise price of $2.98.
• These options vest on the earlier of the one-year anniversary of the grant date (September 3, 2024) or the next shareholder annual meeting, contingent upon continuous service.
• Following the transaction, Falberg directly owns derivative securities for 200,801 shares.
• The options expire on September 2, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock option grant, which is neither inherently positive nor negative.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Future Outlook

The vesting of the options is contingent upon the director's continuous service, suggesting an expectation of continued involvement with the company.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their compensation strategy.
• The size of the grant (200,801 shares) would typically be evaluated against industry averages for director compensation at companies with similar market capitalization and growth prospects.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment as it aligns the director's interests with those of the shareholders.

Key Dates